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Background: Infection with HIV-1 results in marked immunologic insults and structural damage to the
intestinal mucosa, including compromised barrier function. While the development of highly active
antiretroviral therapy (HAART) has been a major advancement in the treatment of HIV-1 infection, the need
for novel complementary interventions to help restore intestinal structural and functional integrity remains
unmet. Known properties of pre-, pro-, and synbiotics suggest that they may be useful tools in achieving this
goal.
Methods: This was a 4-week parallel, placebo-controlled, randomized pilot trial in HIV-infected women on
antiretroviral therapy. A synbiotic formulation (Synbiotic 2000W) containing 4 strains of probiotic bacteria (1010
each) plus 4 nondigestible, fermentable dietary fibers (2.5 g each) was provided each day, versus a fiber-only
placebo formulation. The primary outcome was bacterial translocation. Secondary outcomes included the
levels of supplemented bacteria in stool, the activation phenotype of peripheral T-cells and monocytes, and
plasma levels of C-reactive protein and soluble CD14.
Results: Microbial translocation, as measured by plasma bacterial 16S ribosomal DNA concentration, was not
altered by synbiotic treatment. In contrast, the synbiotic formulation resulted in significantly elevated levels of
supplemented probiotic bacterial strains in stool, including L. plantarum and P. pentosaceus, with the
colonization of these two species being positively correlated with each other. T-cell activation phenotype of
peripheral blood lymphocytes showed modest changes in response to synbiotic exposure, with HLA-DR
expression slightly elevated on a minor population of CD4+ T-cells which lack expression of HLA-DR or PD-1.
In addition, CD38 expression on CD8+ T-cells was slightly lower in the fiber-only group. Plasma levels of
soluble CD14 and C-reactive protein were unaffected by synbiotic treatment in this study.
Conclusions: Synbiotic treatment for 4 weeks can successfully augment the levels of probiotic species in the
gut during chronic HIV-1 infection. Associated changes in microbial translocation appear to be absent, and
markers of systemic immune activation appear largely unchanged. These findings may help inform future
studies aimed at testing pre- and probiotic approaches to improve gut function and mucosal immunity in
chronic HIV-1 infection.
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Infection with human immunodeficiency virus-1 (HIV-1)
results in substantial dysfunction of the intestinal mu-
cosa. During the past decade it has become clear that
the intestinal mucosa is a site of vigorous virus replica-
tion beginning in the very early stages post-infection,
and emerging from this storm of replication is a mucosa
with a severely depleted CD4+ T-cell population as well
as other notable gastrointestinal (GI) pathologies [1].
HIV-associated histopathology in the GI tract includes
collagen deposition [2], degeneration of smooth muscle
and enteric autonomic nerve fibers [3-5], and abnormal
enterocyte morphologies such as villous blunting, vacuo-
lization, and smooth endoplasmic reticulum changes
[5,6]. In addition, HIV-1 and simian immunodeficiency
virus (SIV) cause direct damage to intestinal epithelial
cells [7,8], and gene expression studies of the GI mucosa
have revealed HIV-associated upregulation of genes
involved in inflammatory and apoptosis pathways [9]. In
terms of the intestinal microbiota, HIV infection has
been associated with depressed levels of beneficial bifi-
dobacteria and lactobacilli, and elevated levels of oppor-
tunistic pathogens including Pseudomonas aeruginosa
and Candida albicans [10]. In light of this broad set of
impacts on the intestinal mucosa, it is not surprising
that basic functional tasks of the gut, such as efficient
nutrient absorption and the maintenance of intestinal
barrier function, are significantly compromised [11-14].
Highly active antiretroviral therapy (HAART) regi-
mens have proven to be very successful in terms of sup-
pressing virus replication and promoting CD4+ T-cell
reconstitution, but HAART does not provide a solution
to the broad damage sustained by the GI mucosa. In
fact, in the context of HIV treatments there are no ther-
apies available to support or initiate the multiple repair
processes which would be needed to restore full struc-
tural and functional integrity to the gut. In the absence
of interventions to support such repair, there must cer-
tainly be health consequences to HIV-infected indivi-
duals. One such consequence is that HIV infection, even
in the context of HAART, is associated with elevated mi-
crobial translocation from the gut into the circulation as
evidenced by elevated plasma lipopolysaccharaide (LPS)
and bacterial DNA levels [11,15]. In pathogenic SIV in-
fection of rhesus macaques, a model system for HIV-1
infection in humans, circulating LPS is also elevated
[11], and both bacteria and LPS can be detected in the
intestinal lamina propria and mesenteric lymph nodes
by immunostaining [16]. Importantly, both plasma LPS
and plasma bacterial ribosomal 16S DNA levels in HIV
patients are correlated with systemic immune activation
markers such as CD8+ T-cells expressing both CD38
and HLA-DR [11,15]. Thus, a model has emerged where
compromised gut barrier function results in elevatedcirculating LPS which fuels immune activation during
chronic HIV-1. The importance of this is that immune
activation, especially as measured by coexpression of
CD38 and HLA-DR on CD8+ T-cells, is a better pre-
dictor of HIV disease progression than viral load or
CD4+ T-cell loss [17]. Among HIV-infected patients,
microbial translocation has also been found to be asso-
ciated with sluggish CD4+ T-cell reconstitution in the
context of HAART [15,18]. Thus, reduced gut barrier
function in HIV infection has important health implica-
tions which point to a need to develop interventions to
complement HAART.
Pre- and probiotics are prime candidates for therapies
which may offer improvement in GI barrier function
during chronic HIV-1 infection. A probiotic can be
defined as ‘a live microbial food ingredient that is benefi-
cial to health’ [19], and a prebiotic as ‘a nondigestible
food ingredient that beneficially affects the host by se-
lectively stimulating the growth and/or activity of one or
a limited number of bacteria in the colon, and thus
improves host health’ [20]. When pre- and probiotics are
provided together they constitute a ‘synbiotic’ based on
the potential to synergize. Broadly speaking, pre- and
probiotics have been shown to exert numerous positive
effects on GI function and immunity in human and ani-
mal studies. Examples of this, which are relevant to
HIV-induced changes in the gut, include the ability of
probiotics to: 1) maintain or enhance tight junction
protein expression [21-24], 2) induce protective mucin
production [25-27], 3) protect against enteroinvasive
bacterial pathogens [26,28-30], and 4) decrease stress-
induced bacterial translocation [31-34].
In the present pilot study, we evaluated Synbiotic 2000W
(Medipharm, now owned by Synbiotic AB, Kustvägen 13,
Sweden) in a double-blind, randomized, placebo-controlled
parallel intervention. In previous human studies of trauma
resulting from elective surgery or accidental injury, this for-
mulation has been associated with significantly fewer
bacterial infections and reduced need for antibiotic use
[35-37], shorter duration of hospital stay [35], and reduced
plasma levels of endotoxin and inflammatory cytokines
[31,35]. The hypothesis for the present study was that in-
gestion of this synbiotic formulation would 1) enhance the
levels of supplemented probiotic species in the gut, 2) im-
prove gut barrier function as indicated by reduced
microbial translocation, and 3) reduce systemic immune
activation. We present results from assessments in a small
cohort of HIV-1 infected women taking antiretroviral
medications.
Methods
Ethics Approval and Study Design
This study was conducted with the approval of the Insti-
tutional Review Board of the University of California,
Schunter et al. BMC Complementary and Alternative Medicine 2012, 12:84 Page 3 of 15
http://www.biomedcentral.com/1472-6882/12/1/84Davis, USA, School of Medicine. Written informed con-
sent was provided by all participants in the study.
This was a randomized, double-blind, placebo-
controlled study. It was a parallel design, 4-week pilot
study with an enrollment target of 38 subjects. The trial
was conducted at the Center for AIDS Research, Educa-
tion, and Services (CARES) in Sacramento, CA, between
the dates of June 2008 and September 2009. There were
no other trial sites.
Inclusion criteria were: 1) HIV seropositive, 2) adult fe-
male, 3) currently taking antiretroviral medications, and
4) blood CD4 count >200 cells/μl. These inclusion cri-
teria were modified from an original form which called
for a blood CD4 count of <500 cells/μl and for race lim-
ited to African-American and Caucasian. The change to
the final form made the study available to a wider group
of potential subjects without compromising the achieve-
ment of the scientific aims of the study. Exclusion cri-
teria included: 1) Acquired immune deficiency syndrome
(AIDS)-defining conditions, 2) current use of oral anti-
biotics, and 3) presence of inflammatory bowel disease
or other known GI pathology.
The study interventions were 1) Synbiotic 2000W and
2) Fiber-only (the prebiotic components of Synbiotic
2000W alone). A single packet of Synbiotic 2000W con-
sists of 4 strains of probiotic bacteria (1010 each) plus 4
nondigestible, fermentable dietary fibers (2.5 g each).
The bacteria are Pediococcus pentosaceus 5–33:3, Leuco-
nostoc mesenteroides 32–77:1, Lactobacillus paracasei
subsp paracasei 19, and Lactobacillus plantarum 2362.
The fibers include betaglucan, inulin, pectin, and resist-
ant starch. The study intervention products were a gift
of Medipharm, which had no other role in the study or
its analysis.
The informed consent process was administered by the
study coordinator. Subsequently, subjects made an appoint-
ment to begin the 4 week trial. At the initial visit, the study
coordinator referred to a randomization schedule for as-
signment of participants to either the synbiotic or the pre-
biotic control interventions, and provided a supply of 30
packets to take home. Subjects were advised on how to
store the packets and how to ingest the contents. Plastic
tumblers with tight fitting lids were offered for dissolving
the preparations in water or any beverage of the subjects’
choice, with the exception of alcoholic or hot drinks. A
recordkeeping sheet was provided for participants to make
an entry each day, noting their beverage of choice in ingest-
ing the product. Subjects also indicated the frequency of
probiotic-containing foods in their typical diet. Participants
were reminded to notify the study coordinator in the event
they needed to take oral antibiotics as this was one of the
exclusion criteria. Sample collection at the initial visit
included fresh stool and venous blood. Stool sampling was
a modification to the original protocol, with 11 subjectsfrom each group included in this analysis. This modification
allowed for the determination of supplemented probiotic
species in stool.
Approximately one week after the first visit, a follow-up
phone call was made to the participants to check for any
problems or concerns, and to offer encouragement in light
of undesirable gas that can sometimes result from inges-
tion of these products. The second and final visit was on
day 28, when subjects: 1) returned their recordkeeping
sheet, 2) provided a fresh stool sample, and 3) supplied a
venous blood sample.
Randomization and blinding
Randomization to blocks was stratified based on subject-
described race categories: 1) African-American, 2)
Caucasian, and 3) other. These race categories were chosen
based on the predominant makeup of the population of po-
tential subjects visiting the CARES clinic. A randomization
schedule was established by the primary investigator using
a computer-based random number generator. The two
interventions were supplied in daily dose packets with the
same appearance other than the designation of cocktail A
or cocktail B. Because the PI had knowledge of the iden-
tities of these cocktails, they were further coded to ‘X’ or
‘O’ and assembled into bags containing 30 packets of a
given intervention (described above). The recoding scheme
and bagging process was blind to all study personnel and
was conducted by staff having no subsequent involvement
in the study. During the course of the study, participants
and the entire research staff remained blinded to treatment
assignments, including the study coordinator, health care
providers, study collaborators, student assistants, and the
primary investigator.
Outcomes and Sample Size
The primary outcome measure was the change from
baseline in plasma bacterial DNA concentration.
Secondary outcomes included changes in T-cell and
monocyte phenotypes, blood CD4+ T-cell count,
plasma soluble CD14 (sCD14), and plasma C-reactive
protein (CRP). Shortly after the start of the study,
stool collection was implemented in order to measure
stool levels of supplemented probiotic bacteria as an
additional secondary outcome. Sample size was based
on power analysis using published data on plasma
LPS levels in HIV infection [11] and employing 80%
power, 5% level of significance, and an estimated
treatment effect of 0.6 relative to the control. These
parameters indicated a sample size of approximately
15 per group.
Clinical Laboratory Assays
Blood CD4+ T-cell count was determined by the
clinical laboratory at the University of California,
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not measured as part of the study, but the most re-
cent viral load relative to the start of the study was
taken from the subjects’ medical record.Specimen Processing and DNA Isolation
Blood was collected into EDTA-containing tubes, centri-
fuged 10 min at 250 x g to obtain platelet-rich plasma,
then processed using Ficoll-PaqueTM (GE Healthcare
Bio-Sciences, Sweden) to derive peripheral blood mono-
nuclear cells (PBMC). Plasma was stored at −80 °C and
PBMC were cryopreserved in a liquid nitrogen freezer
until later analyses. Aliquots of fresh stool weighing ap-
proximately 200 mg were taken using a 1 cc tuberculin
syringe with the luer tip cut off, then placed in 2 ml
microfuge tubes and stored at −80 °C until DNA
isolation.
DNA was isolated from plasma using DNeasyW Blood
& Tissue isolation kits (Qiagen, Maryland, USA) accord-
ing to the manufacturer’s instructions. Each DNA prep-
aration was made utilizing an input of 200 μl plasma
that had been stored at −80 °C, and using a final elution
volume of 200 μl at the end of the isolation protocol.
DNA samples were stored at −80 °C until qPCR analysis.
Stool DNA was isolated using the QiAampW DNA Stool
Mini Kit (Qiagen). The temperature of the lysing step
was increased to 95 °C to improve the yield of DNA
from gram positive bacteria in the specimens. DNA sam-
ples derived from stool were stored at −80 °C until qPCR
analysis.Real-Time qPCR of Plasma Bacterial 16S DNA
Quantitative real-time PCR analysis of DNA samples
from plasma was performed using a Roche LightCycler
2.0 coupled with FastStart DNA Master SYBR Green I
detection. Reactions consisted of 10 μl input template
(see above), 4 mM MgCl2, 0.5 μM of each primer, and
buffered SYBR Green mix in a total reaction volume of
20 μl. Universal 16S bacterial primers were F909 5’-
ACTCAAAKGAATTGACGG-3’ [38] and R1114 5’-
GGGTTGCGCTCGTTRC-3’ [39]. The PCR conditions
consisted of: Initial denaturation at 95 °C for 5 min then
45 cycles, each consisting of denaturation at 95 °C for
10 s, annealing at 50 °C for 5 s, and extension at 72 °C
for 12 s. At the completion of the run melting curves
were generated. Fluorescence was monitored at 530 nm
and analyzed using LightCycler Software V 4.1 (Roche
Diagnostics, Indiana, USA). A negative control lacking
template, plus plasmid standards for absolute quantita-
tion, were included with every set of reactions. In
addition to absolute quantitation, samples were also
evaluated for the melting temperature (Tm) of amplified
products using LightCycler Software V 4.1.Real-Time qPCR of Synbiotic Bacterial Strains in Stool
DNA
Using primers specific to the 4 bacterial species contained
in the synbiotic supplement (see below), real-time qPCR
was carried using a LightCycler 2.0 (Roche Diagnostics).
Each reaction mixture (10 μl) contained 0.5 μM of each
primer, 1.2 μl magnesium chloride, 1 μl LightCyclerW Fas-
tStart DNA Master SYBR Green I and 1 μl (10 ng) of stool
DNA. The PCR amplification program was 95 °C for
5 min, 45 cycles of 95 °C for 10 s, 58 °C for 5 s, 72 °C for
12 s, followed by 1 cycle of 65 °C for 15 s, and finally 40 °
C for 30 s. An external standard curve for each of the four
lactobacilli strains was developed for absolute quantita-
tion. The plasmid stock solution of each strain, which con-
tained approximately 1011 plasmid copies, was serially
diluted in 0.02 μg/μl yeast RNA. 1 μl of each dilution was
used in a total PCR volume of 10 μl to create the external
standard curves. For quantitation of total bacterial 16S
copies in stool samples, the standard curve for the Pedio-
coccus pentosaceus plasmid was used.
Design of primers for Real-Time qPCR of supplemented
probiotic bacteria in stool
The four lactobacilli 16S rRNA gene sequences were com-
pared with reference sequences from the Ribosomal Data-
base Project release 9 which contained over 500,000 16S
rRNA sequences. For each of the 4 lactobacilli strains a
primer pair for the hypervariable region of the 16S rRNA
gene sequence was designed using the software MacVec-
tor 9.5.2. To test the specificity of the primers the software
Probe Match was used. The primers used for qPCR were:
Pediococcus pentosaceus - sense: Ppent_117s (5’-ACACG
AAGTGAGTGGCGAACG-3’), antisense: Ppent_271a
(5’-CGGGTCCATCCAGAAGTGATA-3’), Lactobacillus
plantarum - sense: Lplant_221s (5’-AGTTTGAAAG
ATGGCTTCGGCT-3’), antisense: Lplant_334a (5’-GATT
ACCCTCTCAGGTCGGCTA-3’), Leuconostoc mesenter-
oides - sense: Lmes_82s (5’-GCACCTTTTCAAGTGA
GTGGCGAAC-3’), antisense: Lmes_162a (5’-TCTGTTTC
CAAATGTTATCCCCAGC-3’), Lactobacillus paracasei
spp. paracasei - sense: Lpara_150s (5’-AGTGGGGGA-
TAACATTTGGAAACAG-3’), antisense: Lpara_296a (5’-
CGCCTTGGTGAGCCATTACCTC-3’). To determine
the total bacterial number in the stool the universal pri-
mers UniF334 (5’-ACTCCTACGGGAGGCAGCAGT-3’)
and UniR514 (5’-ATTACCGCGGCTGCTGGC-3’) were
used which detect about 80 – 85 % of the microflora in
human stool.
Construction of Plasmids for Absolute Quantitation in
Real-Time qPCR
For plasmid standards applied to the measurement of
stool levels of supplemented probiotic bacteria, genomic
bacterial DNA was first isolated from Synbiotic 2000W
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water and then using the QIAamp DNA Stool Mini Kit
(Qiagen) to obtain DNA. Next, 16S rRNA genes were
amplified by conventional PCR using primers 27F (5’-A
GAGTTTGATCCTGGCTCAG -3’) and 1492R (5’-GG
TTACCTTGTTACGACTT-3’) which bind to conserved
regions of the 16S rRNA gene. The settings for the PCR
were 35 cycles at 94 °C for 30 seconds, 50 °C for 30 sec-
onds and 72 °C for 2 min followed by a final elongation
at 72 °C for 7 min. The PCR product was then purified
(QIAquick PCR Purification Kit, Qiagen), and after en-
zymatic blunt end formation the resulting product was
resolved with a preparative 1 %-agarose gel. Following
extraction from the gel (QIAquick Gel Extraction Kit,
Qiagen), the blunt end PCR insert was ligated into
pBluescript II SK cloning vector and used to transform
Escherichia coli DH5α cells (Invitrogen, Carlsbad, CA,
USA). Plasmids were isolated with the QIAprep Spin
Miniprep Kit (Qiagen), sequenced with a Big Dye Ter-
minator V3.0 sequencing chemistry (Applied Biosystems,
Carlsbad, CA) using vector-specific primers T3 and T7,
and quantitated by absorbance at 260 nm.
Plasmid standards applied to the quantitation of
plasma bacterial DNA were made in the same way as
described immediately above, but by starting with a ran-
domly selected stool DNA preparation from one of the
study participants.Flow Cytometry
Cryopreserved PBMC were thawed and assessed for via-
bility using trypan blue staining. Viability ranged from
87-98% and averaged 95%. With each batch of cells ana-
lyzed, a vial of internal control PBMC was included to
assess run-to-run consistency of staining parameters.
For each subject, PBMC from both the beginning and
end of the study were always thawed, stained and ana-
lyzed in the same batch in order to provide consistency
of analysis. Thawed cells (1–2 x 106) were washed in
PBS and surface stained for 20 min at room temperature
in pre-titered fluorescently labeled antibodies plus Live/
DeadW Fixable Aqua viability stain (Invitrogen,) in PBS
in a total volume of 50 μl. Antibodies included CD3-Pac
Blue (clone UCHT-1) and CD38-PE (QuantibriteTM,
clone HB7) which were purchased from BD Biosciences
(San Diego, CA, USA). CD4-APC (clone RPA-T4), CD8-
APCAlexa750 (clone RPA-T8) HLA-DR-FITC (clone
TU36), and CD14-Alexa700 (TuK4) were obtained from
Invitrogen. PD-1-PerCP-eFlour710 (clone J105) was pur-
chased from eBioscience (San Diego, CA, USA). Follow-
ing surface staining, cells were washed in PBS/2% fetal
calf serum and suspended in 1% formaldehyde prior to
data acquisition. One hundred thousand lymphocyte
events were acquired on a Becton-Dickinson LSRII flowcytometer equipped with 403 nm, 488 nm and 643 nm
lasers.
Flow cytometry data were analyzed using FlowJo soft-
ware (TreeStar, Ashland, OR, USA). Flourescence-
minus-one stained cells were utilized to clarify gating
where needed. Frequencies of CD4+ and CD8+ T-cells
expressing CD38, HLA-DR, and PD-1 were established.
Calculated frequencies of cell subsets expressing all pos-
sible combinations of these three markers were also
derived using the Boolean gating feature in FlowJo. In
addition to frequencies, the median fluorescence inten-
sity (MFI) of CD38+ populations of T-cells was deter-
mined and converted to antibodies bound per cell using
calibration beads (QuantibriteTM PE Beads, BD Bios-
ciences). Monocytes were also assessed for the MFI of
CD14 and HLA-DR and for CD38 antibodies bound per
cell.
Plasma sCD14 and CRP
Plasma concentrations of sCD14 and CRP were mea-
sured in fresh-thawed plasma using QuantikineW ELISA
kits purchased from R&D Systems (Minneapolis, MN,
USA). Prior to assay, plasma was diluted 1:500 and 1:250
for sCD14 and CRP assays, respectively. Samples were
assayed in duplicate and plates were read on a plate
reader at 450 nm (Versamax, Molecular Devices, Sunny-
vale, CA, USA). Curve fitting of standards and calcula-
tion of sample concentrations was done with SoftMax
Pro software (Molecular Devices).
Statistical methods
Statistical analyses were based on data derived from per
protocol participants; i.e., data from subjects completing
the study without any violations of protocol such as fail-
ure to complete the trial or taking oral antibiotics during
the trial period (See Figure 1 for specific numbers). For
both primary and secondary outcomes, the change from
study baseline for a given parameter was calculated (i.e.,
Day 28 value minus baseline value). These change scores
were compared between the two intervention groups
using a Mann–Whitney test (2-tail in all cases). The sig-
nificance of selected associations was evaluated using
Spearman correlation (2-tail). Linear regression analysis
was used to generate best-fit lines for visual (not statis-
tical) purposes. For all statistical tests p< .05 was con-
sidered significant.
Results
Participant Flow Diagram and Characteristics of Study
Subjects
The flow of participants in the study is shown in Figure 1.
Thirty-eight subjects were assessed for eligibility, with 33
being randomized (1:1) to treatment interventions. The
clinical characteristics of study participants assigned to
N=38 Assessed for eligibility
N=5 Excluded 
Not meeting inclusion criteria (n=2) 
Declined to participate (n=3) 
N=33 Randomized 
N=17 Allocated to Fiber-only
Received intervention (n=17)
Did not receive intervention (n=0) 
N=16 Allocated to Synbiotic 2000
Received intervention (n=16) 
Did not receive intervention (n=0) 
N=4 Lost to follow-up
Withdrew, reason not given (N=3) 
Withdrew due to antibiotics (N=1) 
N=2 Lost to follow-up
Withdrew due to antibiotics (N=2)
N=13 Per protocol N=14 Per protocol
Figure 1 Participant Flow Diagram.
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were similar in terms of the listed characteristics such as
ethnicity, age, years on antiretroviral therapy, years of HIV
seropositivity, baseline blood CD4+ T-cell count, plasma
HIV load, and routine ingestion of cultured foods. Cul-
tured foods included yogurt and other cultured dairy
products, sauerkraut, kimchi, miso, tempeh, and others
specified by the subject. All study participants were female
and taking antiretroviral medication. Therefore, most sub-






African American, N (%)
Caucasian, N (%)
Other, N (%)
Mean age, years (SD)
Years HIV seropositive, Mean (SD)
Years on antiretroviral therapy, Mean (SD)
Blood CD4 count, cells/μl, Mean (SD)
Viral load <50 copies/ml, N (%)
Viral load >50 copies/ml, N (Geometric Mean, SD)
Cultured foods consumption. Mean servings/week (SD)(<50 copies/ml), although 2–4 subjects per group did
have detectable low level viremia. The geometric mean
viral load per group for these few subjects is shown in
Table 1.
Microbial translocation is quantitatively unaffected by
synbiotic intervention
To assess microbial translocation, we measured bacterial
ribosomal DNA in plasma via real-time qPCR of a highly
conserved sequence. Raw data on plasma concentrationFiber only Group Synbiotic Group
13 (100) 14 (100)
none none
6 (46.2) 7 (42.9)
5 (38.5) 6 (50.0)
2 (15.4) 1 (7.1)
48.8 (6.1) 46.4 (8.0)
12.3 (6.8) 15.2 (8.6)
7.0 (4.7) 8.7 (5.5)
588 (309) 685 (249)
9 (69.2) 12 (85.7)
4 (581, 6257) 2 (83, 1.4)
5.3 (4.1) 6.1 (5.4)
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Figure 2A-C. An average of approximately 500 bacterial
ribosomal 16S copies/μl plasma was measured at base-
line and at Day 28 in each of the two intervention
groups (Figure 2A and 2B). Evaluation of change scores
indicated that the means of these changes were not sta-
tistically different between the two treatment groups
(Figure 2C).
Melting profiles of amplified products can give an in-
direct indication of whether there are qualitative (rather
than quantitative) differences in the products amplified
from different time points. We therefore analyzed melt-
ing profiles to establish melting temperatures (Tm); in
cases where there was more than a single peak, the pri-
mary peak was selected for analysis. Raw data and calcu-
lated change scores are shown in Figure 2D-F. The
mean Tm was remarkably similar for both groups at
both time points of the study, averaging close to 86.7 °C
(Figure 2D and 2E). Change values calculated from these
data are shown in Figure 1F and reveal that the average
change in Tm for the two interventions was close to
zero and was not statistically different (Figure 2F). Thus,
using plasma 16S rDNA as an indicator of microbial
translocation, we observed neither qualitative nor quan-
titative changes associated with synbiotic exposure rela-
tive to the fiber-only control.
Plasma bacterial 16S rDNA concentration in HIV
patients has previously been shown to be correlated with
coexpression of CD38 and HLA-DR on CD8+ T-cells
[15]. Although our plasma 16S data did not indicate an
effect of the synbiotic intervention on microbial trans-
location, it was of interest to explore whether in our co-
hort pretreatment levels of plasma 16S rDNA were
related to pretreatment T-cell activation phenotypes as
established by flow cytometry. Out of several possible
activation phenotypes, we determined that the frequency
of CD8+CD38+ T-cells was most closely related to
plasma bacterial 16S rDNA concentration, (p = .030,
Figure 2G), supporting the concept of a relationship be-
tween microbial translocation and T-cell immune
activation.
Synbiotic treatment results in elevated fecal probiotic
bacteria
While the two interventions did not differ in terms of
microbial translocation, it was possible that the synbiotic
formulation altered the levels of supplemented probiotic
bacteria in the gut. To this end, the presence of each
probiotic strain was determined in fecal samples from
11 subjects in each group using real-time quantitative
PCR (Figure 3). Of the four species in the synbiotic for-
mulation, L. plantarum and P. pentosaceus showed sig-
nificant increases (p= .001, p= .036, respectively) in stool
concentration compared to the fiber-only intervention(Figure 3A, 3B), while the changes in L. mesenteroides
and L. paracasei did not differ between the two
treatments (Figure 3C, 3D). To explore whether the sig-
nificant increases in L. plantarum and P. pentosaceus
were related to each other, a Spearman correlation was
calculated and revealed a significant positive correlation
between the two species (Figure 3E, p= .002). Thus, the
synbiotic intervention successfully modulated stool
levels of probiotic bacteria which were also correlated
with each other.
T-cell and monocyte activation phenotypes remain
largely unchanged with synbiotic intervention
We evaluated peripheral blood T-cell and monocyte
phenotypic markers using flow cytometry, with Figure 4
showing the gating pathway utilized for the analysis of
T-cells. For both CD4+ and CD8+ T-cells, gates were
established for cells expressing the activation markers
HLA-DR and CD38, and the T-cell exhaustion marker
PD-1. The frequency of cells in these gates was analyzed
in terms of the change from baseline for each subject in
each intervention group. For a more detailed analysis,
these three gates were also entered into Boolean com-
bination analysis which generated 9 populations consist-
ing of all possible combinations of expression (or not) of
the 3 surface markers. A separate gating pathway using
CD14 to identify monocytes was also employed (not
shown). The monocyte population was assessed for the
median fluorescence intensity (MFI) of CD14 and HLA-
DR.
The expression patterns of CD38, HLA-DR, and PD-1
on CD4+ and CD8+ T-cells, the expression of CD14,
CD38, and HLA-DR on monocytes, and blood CD4
count values are summarized in Table 2. The values are
not change scores; rather, they are data corresponding to
baseline and Day 28 for the two groups. Analysis of
change scores yielded the p values in the far right col-
umn of Table 2. T-cell and monocyte activation pheno-
types were remarkably stable during the study period for
both of the interventions. One exception to this stability
was a modest, but significant, synbiotic-associated in-
crease in HLA-DR expression on a minor population of
CD4+ T-cells that were negative for CD38 and PD-1
(p= .027, Table 2 and Figure 5A). A second finding was
a difference in the change in CD38 antibodies bound per
cell on CD8+ T-cells (p= .044, Figure 5B). The synbiotic
group showed an average change of +19 antibodies
bound per cell while the Fiber-only group had a change
of −235.
Given the small group sizes and the fact that fecal
levels of supplemented bacteria varied among subjects in
the synbiotic arm, we explored whether there could be
correlations between fecal changes in L. plantarum or P.
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Figure 2 Plasma bacterial 16S rDNA levels, Tm values of amplified products, and relationship to immune activation. (A) Plasma 16S
rDNA levels in the fiber-only group at baseline and day 28. (B) Plasma 16S rDNA levels in the synbiotic group at baseline and day 28. (C) Change
scores for plasma 16S values calculated from paired values across the experimental period, presented for each group. (D) Fiber-only group Tm
values at baseline and day 28. (E) Synbiotic group Tm values at baseline and day 28. (F) Tm change scores calculated from paired values across
the experimental period for each intervention. (G) Spearman correlation of pretreatment plasma 16S rDNA concentration with pretreatment
frequency of peripheral CD8+CD38+ T-cells (all subjects at baseline). Horizontal bars denote the mean. N.S., not statistically significant (p> 0.05).
r, Spearman r value.
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http://www.biomedcentral.com/1472-6882/12/1/84evaluate this, we selected parameters from Table 2 where
the p value was less than 0.3 (there were 7 cases of this)and calculated Spearman correlations. Of these, a signifi-











































































































































Figure 3 Changes in fecal levels of supplemented probiotic bacteria. DNA from fresh stool was amplified using primer sets specific to the
supplemented bacteria and also using universal r16S primers to derive total fecal bacterial content. The number of r16S copies of each probiotic
species in relation to one million total fecal r16S copies was calculated and the change in this value from baseline to day 28 shown here. (A)
Lactobacillus plantarum 2362, (B) Pediococcus pentosaceus 5–33:3, (C) Leuconostoc mesenteroides 32–77:1, and (D) Lactobacillus paracasei subsp
paracasei 19, (E) Spearman correlation between changes in P. pent and L. plant (Synbiotic group only). Horizontal bars denote the mean. N.S., not
statistically significant (p> 0.05). r, Spearman r value.
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CD38+ T-cells (Figure 5C) These data suggest a link be-
tween the gut colonization of synbiotic-derived P. pento-
saceus and a drop in T-cell activation phenotype. In
contrast, the significant elevation in HLA-DR expression
on CD4+ T-cells negative for CD38 and PD-1, and the
significant difference in CD38 antibodies bound per cell
on CD8+ T-cells (Table 2 and Figure 5A, 5B) were not
significantly correlated with changes in fecal L. plan-
tarum or P. pentosaceus (data not shown).
Plasma concentrations of sCD14 and CRP are unaltered
by synbiotic treatment
Circulating sCD14, released from monocytes in response
to LPS exposure, as well as CRP produced by the liver,
are both elevated in HIV infection and are each corre-
lated with HIV disease progression [40,41]. These two
factors were therefore measured in plasma using ELISA,with average plasma concentrations at baseline and day
28 being 1.9 and 1.9 μg/ml in the fiber-only group, and
2.1 and 2.0 μg/ml in the synbiotic group. Change values
for each group are detailed in Figure 6, with average
changes indicating no difference between the fiber-only
and synbiotic groups. Levels of TNF-α and γ-IFN were
also measured in plasma using LuminexW and showed
no change in relation to treatment intervention (data
not shown).
Discussion
In this study we selected Synbiotic 2000W based on its
documented activity in protecting hospitalized patients
from infectious complications [35-37] and in reducing
circulating inflammatory cytokines and LPS [31,35].
While the first part of our hypothesis, that probiotic spe-
cies would be enhanced in the gut, was supported, the
proposed drop in microbial translocation and immune































































































Figure 4 Flow cytometry gating pathway for T-cell activation markers. Initial gating was on lymphocytes as approximated by scatter, then
doublets were eliminated. Next, live CD3+ cells were selected, CD14+ cells left behind, then CD4+ and CD8+ cells were gated. For cells in each
of the CD4+ and CD8+ gates, individual gates for HLA-DR, CD38, and PD-1 were then established. The frequencies of these populations were
analyzed as-is, and also after creation of Boolean combinations of these three groups.
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as meaning that the chosen probiotic bacteria are intrin-
sically unable to exert the hypothesized downstream
effects, that is, reduction of microbial translocation and
immune activation. Conversely, our data raise the
question of how much colonization, in terms of magni-
tude and duration, would be required to generate the
hypothesized subsequent effects if they were to occur at
all. To tackle this issue it seems necessary to design fu-
ture studies of this type into two phases, the first being
the testing of multiple formulations with variable dosing
and time frames to establish optimal conditions for
achieving substantial and reproducible enhancement in
probiotic bacteria in the gut of HIV patients. A key issue
to grapple with in this first phase lies in the fact that
there is an enormous array of possible formulations to
choose from. This is a reflection of the large diversity of
probiotic species, the plethora of specific strains with
unique properties, and the formulation of mixtures con-
taining multiple probiotic species. With the addition ofprebiotics as an additional variable, it becomes clear why
the formulations in intervention studies vary so widely.
The good news with this situation is that there is a rich,
diverse palette available to the clinical scientist, while
the negative aspect is that a formulation with bacteria
lacking the desired properties may be chosen. As com-
prehensive studies on intestinal microbiota alterations in
HIV infection become available, it may be possible to
tailor interventions appropriately. These challenges
aside, after establishing optimal formulations in phase
one, the most promising strategies can then be tested in
phase two to determine whether there are beneficial
effects on gut and immune function.
The relevance of the modest changes in activation
phenotypes (Table 2 and Figure 5) is not clear. The sig-
nificant p-values were borderline and may have been
influenced by the use of multiple comparisons. In
addition, the difference in mean changes was small in
both cases of statistical significance. For example, the
phenotype consisting of CD4+ cells expressing HLA-DR
Table 2 T-cell and Monocyte Phenotypes at Baseline and at Day 28
Cell population Parameter Fiber-only Synbiotic
Baseline Day 28 Baseline Day 28 p value
AVG SD AVG SD AVG SD AVG SD
CD4+ T-cells CD4+ T-cell count, cells/μl 627 293 619 337 683 259 697 296 0.862
%CD38+ 56.6 14.5 56.1 14.0 54.4 11.8 52.4 11.9 0.216
CD38 Abs bound/cell 3737 980 3626 807 3353 1158 3276 1058 0.790
%DR+ 7.4 5.6 7.8 5.5 6.1 5.4 6.5 4.9 0.827
%PD1+ 23.5 10.5 24.5 9.2 25.2 12.2 26.0 11.7 0.753
PD1, MFI 1315 282 1316 200 1212 152 1232 152 0.610
%CD38+DR+ 3.8 4.2 4.1 3.8 2.7 1.9 2.8 1.5 0.482
%CD38+DR+PD1+ 2.5 3.4 2.7 3.1 1.6 1.2 1.7 1.1 0.452
%CD38+DR+PD1- 1.3 1.1 1.5 1.1 1.1 0.9 1.1 0.6 0.981
%CD38+DR-PD1+ 6.8 4.9 6.8 3.8 8.5 8.0 8.5 7.8 0.716
%CD38+DR-PD1- 46.0 16.1 45.1 14.4 43.2 13.6 41.1 12.7 0.254
%CD38-DR+ PD1+ 1.7 1.1 1.8 1.3 1.5 1.5 1.6 1.3 0.865
%CD38-DR+ PD1- 1.9 1.3 1.8 1.3 1.9 2.6 2.1 2.8 0.027
%CD38-DR-PD1+ 12.5 6.1 13.1 6.5 13.6 4.9 14.3 5.0 0.981
CD8+ T-cells %CD38+ 54.3 17.8 54.4 16.7 51.1 15.1 49.3 15.2 0.680
CD38, Abs bound/cell 2099 1365 1864 864 1803 661 1823 780 0.044
%DR+ 18.9 19.0 19.0 16.9 14.0 11.1 15.7 12.1 0.254
%PD1+ 28.5 12.5 29.4 13.3 20.8 9.4 23.7 11.4 0.275
PD1, MFI 1423 211 1423 225 1280 163 1329 212 0.235
%CD38+DR+ 13.4 15.5 13.5 13.5 8.2 6.0 9.1 7.3 0.369
%CD38+DR+PD1+ 8.1 11.0 8.2 9.7 3.5 2.9 4.3 4.7 0.512
%CD38+DR+PD1- 5.4 5.4 5.3 4.8 4.6 4.2 4.9 4.4 0.753
%CD38+DR-PD1+ 6.5 4.8 7.0 5.1 5.7 5.3 6.4 6.5 0.680
%CD38+DR-PD1- 34.4 13.9 33.9 13.2 37.3 11.2 33.8 10.6 0.225
%CD38-DR+ PD1+ 2.7 3.0 2.8 2.8 2.2 2.5 2.5 2.9 0.903
%CD38-DR+ PD1- 2.7 3.5 2.7 3.1 3.6 6.3 4.1 7.0 0.423
%CD38-DR-PD1+ 11.2 7.2 11.4 7.6 9.3 4.8 10.5 4.9 0.482
Monocytes CD14, MFI 13092 2255 12660 2176 13126 2323 13089 1855 0.544
CD38, Abs bound/cell 11229 1868 11094 1658 11537 2764 11138 2458 0.320
HLA-DR, MFI 10250 4641 9827 4393 10218 5988 9952 4079 0.544
p values refer to the comparison between Fiber-only and Synbiotic in the change from baseline. p values less than 0.05 are shown in bold font.
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changed a small amount (from 1.9 to 2.1 % of CD4+ T-
cells). It would seem that if the modest change in this
population in the synbiotic arm was a result of the syn-
biotic intervention then a correlation between this
phenotype and stool levels of supplemented bacteria
would be evident, which was not the case. Likewise, the
other treatment-associated change, CD38 antibodies
bound per CD8+ T-cell, did not correlate with stool pro-
biotic bacteria either. Furthermore, the major activation
phenotypes that we would have predicted to change in
response to the synbiotic intervention (CD4+ and CD8+
T-cells double positive for HLA-DR and CD38)
remained stable. Thus, the significance of the observed
small shifts in T-cell subsets, and whether they actuallyresulted from experimental intervention remains in
question.
Measuring microbial translocation requires accurate
measurement of microbial constituents such as LPS or
bacterial DNA in circulation. We chose to measure bac-
terial ribosomal 16S levels in order to take advantage of
the reproducible and quantitative nature of real-time
PCR. With this approach it is important to bear in mind
that what is being measured is the presence of a highly
conserved DNA sequence, 204 bp in our case, and not
necessarily the presence of entire bacterial genomes or
intact bacteria in circulation. Other studies have
reported elevated plasma LPS and bacterial r16S concen-
tration in HIV patients compared to HIV seronegatives







































































































Figure 5 Changes in CD4+ T-cell markers and association with level of supplemented bacterial in stool. Surface expression of HLA-DR,
CD38 and PD-1 were determined on peripheral blood lymphocytes using flow cytometry. These markers were quantified on CD4+ and CD8+
cells globally, and also using Boolean analysis (see Methods and Table 2) (A) Change in percent T-cells CD4+CD38-HLADR+PD1-, (B) Change in
number of CD38 antibodies bound per cell on CD8+ T-cells, (C) Within the Synbiotic group, correlation of the changes in CD38 expression on
CD4+ T-cells with the change in fecal P. pentosaceus. Horizontal bars denote the mean. r, Spearman r value.
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http://www.biomedcentral.com/1472-6882/12/1/84seropositive, we also measured r16S levels in the plasma
of 10 volunteers at low-risk for HIV infection and found
the average concentration to be reduced by 50% (data
not shown). Related to bacterial translocation is the
emerging surrogate marker sCD14 which is released
from monocytes in response to LPS exposure, and inHIV patients is correlated with disease progression [41].
Our primary endpoint of microbial translocation was
therefore assessed both directly via bacteria r16S and in-
directly using the host factor sCD14. Data from these
two methods support the conclusion that there was no





















































Figure 6 Changes in soluble CD14 and C-reactive protein.
Plasma was assayed for sCD14 and C-reactive protein using ELISA.
The change in concentration (μg/ml plasma) from baseline to day
28 was calculated for each subject and shown here according to
intervention group. (A) Soluble CD14, (B) C-reactive protein.
Horizontal bars denote the mean. N.S., not statistically significant
(p> 0.05).
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the liver may remove incoming bacteria from the portal
circulation to varying extents and the inclusion of mar-
kers of liver function therefore advisable. In this study,
CRP, made by the liver as an acute phase protein, was
also unaltered by the synbiotic.
Recent studies by other groups support the concept that
pre- and probiotics may have positive impacts on CD4+
T-cell function in HIV infection [42]. For instance, Trois
et. al. tested a probiotic formula containing Bifidobacter-
ium bifidum and Streptococcus thermophilus, administered
daily for 2 months to pediatric HIV patients on antiretro-
viral therapy, and observed a significant rise in blood
CD4+ T-cell count (+118 cells/μl) compared to placebo
(−42 cells/μl) [43]. A significant rise in blood CD4 T-cell
count was also documented in separate studies of HIV in-
fection carried out in Nigeria and Tanzania using a pro-
biotic yogurt containing either L. rhamnosus Fiti [44] or L.
rhamnosus GR-1 plus L. reuteri RC-14 [45]. Interestingly,a subsequent longer term 25 week study using L.
rhamnosus GR-1 plus L. reuteri RC-14 did not reveal a
CD4+ T-cell modulating effect, possibly due to the use of
an encapsulated rather than a yogurt formulation [46]. Im-
portantly, studies performed thus far have demonstrated
safety in the administration of probiotics to HIV patients.
With regard to prebiotics, a pilot randomized 12 week
trial of an oligosaccharide mixture in HAART-naïve HIV
patients revealed reduced activation of peripheral CD4+
but not CD8+ T-cells (as measured by CD25 expres-
sion), but no change in blood CD4 T-cell count [47].
One explanation of these findings is that a drop in
CD4+ T-cell activation may precede a subsequent,
slower rise in CD4 count. In fact, in patients initiating
HAART with CD4+ T-cell counts greater than 200 cells/
μl, CD38 expression on peripheral CD4+ T-cells drops
significantly prior to a rise in blood CD4 T-cell count
[48]. Further, this pattern does not hold true for CD8+
T-cells, which lose CD38 expression more slowly after
initiation of HAART. Given this pattern it seems likely
that an additional incremental reconstitution of CD4+
T-cells in response to a pre- or probiotic intervention
may be preceded by an initial drop in CD38 expression
on CD4+ T-cells.
The present study had several limitations. First, be-
cause it was a pilot study the number of subjects en-
rolled was small and we focused on patients taking
antiretroviral drugs. Had we been able to include
patients with AIDS-defining characteristics, a group pre-
viously shown to have higher levels of immune activa-
tion and bacterial translocation than those taking
antiretroviral drugs [11,15], the effects of the synbiotic
may have been more clear. Another issue is that there
was not a mechanism to reliably assess compliance,
other than the subjects’ personal record keeping on
ingesting the formulations which consistently indicated
full compliance. Compliance seemed especially relevant
given the unusual texture of the interventions and their
tendency to produce intestinal gas, especially during the
first week. A third limitation was the placebo being
made up of the fiber component of the synbiotic. While
this formulation did make it possible to implement
double-blinded assignments, the fact that fiber alone can
exert biological effects renders it a less than optimal pla-
cebo. Nevertheless, any differences between synbiotic
and fiber-only can be taken as due to the probiotic com-
ponent of the synbiotic. An additional limitation is that
the measurement of circulating bacterial ribosomal 16S
levels by qPCR does not yield information on the spe-
cific types of bacteria that are being translocated. The
inclusion of sequencing to yield this information in fu-
ture studies would be informative. Lastly, it was beyond
the scope of this study to obtain intestinal mucosal biop-
sies. In response to pre-, pro- and synbiotics, some of
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phenotype and function may occur in the intestinal mu-
cosa, and in this study we would have missed them.Conclusion
Treatment of HIV-1 infected subjects with a synbiotic
for 4 weeks can successfully augment the levels of pro-
biotic species in the gut, while associated changes in mi-
crobial translocation appear to be absent, and markers
of systemic immune activation are largely unchanged.
These data help provide a foundation for future studies
aimed at optimizing synbiotic formulations and treat-
ment schedules in HIV patients. With this information
in hand, it will then be possible to determine whether
synbiotics can improve gut barrier function and reduce
chronic immune activation in this population. We re-
main optimistic that synbiotics may constitute an im-
portant complementary approach to antiretroviral
therapy in the future.
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